Last reviewed · How we verify

NCT05599178

Doppler Findings in the Fetal Cerebral Blood Vessels (VA/MCA) Within 24 Hours Before Delivery and Relation With Perinatal Outcome.

Recruiting now Last updated 1 July 2024
What this trial tests

trial testing Ultrasound examination in early labor in Ultrasonography, Doppler in 120 participants. Currently enrolling.

Timeline
23 December 2022
Primary endpoint
30 September 2025
31 December 2025

Quick facts

Lead sponsorUniversitaire Ziekenhuizen KU Leuven
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment120
Start date23 December 2022
Primary completion30 September 2025
Estimated completion31 December 2025
Sites1 location across Belgium

Drugs / interventions tested

Conditions studied

Sponsor

Universitaire Ziekenhuizen KU Leuven — full company profile →

Who can join

18 and older, female only, with Ultrasonography, Doppler or Obstetric Labor Complications. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

1. Assess differences in flow patterns in the fetal cerebral blood vessels within 24 hours before delivery between fetuses with a normal vs. adverse perinatal outcome. 2. Explore maternal and/or fetal characteristics that might influence technical feasibility of doppler sonography of the fetal cerebral blood vessels in early labor at term. 3. Assess reliability of the technique by measuring intra- and inter-observer variation in a subset of participants.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Ultrasonography, Doppler

Currently open trials in the same condition.

Other Universitaire Ziekenhuizen KU Leuven trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05599178.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing